Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 415,652
  • Shares Outstanding, K 83,970
  • Annual Sales, $ 170 K
  • Annual Income, $ -23,300 K
  • 36-Month Beta 2.35
  • Price/Sales 2,431.82
  • Price/Cash Flow N/A
  • Price/Book 2.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +5.59%
on 12/07/17
5.72 -14.16%
on 11/14/17
-0.71 (-12.63%)
since 11/13/17
3-Month
4.65 +5.59%
on 12/07/17
7.60 -35.39%
on 10/13/17
-1.29 (-20.81%)
since 09/13/17
52-Week
2.02 +143.07%
on 12/22/16
10.54 -53.42%
on 03/13/17
+2.12 (+75.99%)
since 12/13/16

Most Recent Stories

More News
Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index

Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI), which will become effective...

AUP.TO : 6.28 (-2.64%)
AUPH : 4.91 (-0.81%)
IBB : 106.72 (+0.91%)
Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 16, 2017 / U.S. markets dropped sharply Wednesday, with the Dow and S&P 500 posting its largest daily loss since September, as sliding oil prices dragged down the...

AUPH : 4.91 (-0.81%)
ACHN : 2.89 (+2.12%)
Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights

--Trials in FSGS, MCD and Dry Eye to begin in the first half of 2018

AUP.TO : 6.28 (-2.64%)
AUPH : 4.91 (-0.81%)
Aurinia Pharmaceuticals Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017...

AUPH : 4.91 (-0.81%)
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

AUPH : 4.91 (-0.81%)
Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select...

AUP.TO : 6.28 (-2.64%)
IPCI.TO : 0.93 (-4.12%)
IMV.TO : 2.01 (-3.83%)
AUPH : 4.91 (-0.81%)
ONC.TO : 0.77 (unch)
IPCI : 0.74 (-1.33%)
Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017

Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its third quarter 2017 financial results on Tuesday, November 14, 2017, after the market closes....

AUP.TO : 6.28 (-2.64%)
AUPH : 4.91 (-0.81%)
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome

--R&D Day Featuring KOLs in Nephrology and Ophthalmology Will be Webcast Today at 8:30a.m. ET in New York

AUP.TO : 6.28 (-2.64%)
AUPH : 4.91 (-0.81%)
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

Aurinia Pharmaceuticals (AUPH) needs Investors to pay close attention to the stock based on moves in the options market lately.

AUPH : 4.91 (-0.81%)
Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session

Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.

AUPH : 4.91 (-0.81%)
MEIP : 2.12 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 5.14
1st Resistance Point 5.03
Last Price 4.91
1st Support Level 4.80
2nd Support Level 4.68

See More

52-Week High 10.54
Fibonacci 61.8% 7.29
Fibonacci 50% 6.28
Fibonacci 38.2% 5.27
Last Price 4.91
52-Week Low 2.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.